Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteEnasidenib (AG-221) is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzyme.
More Information Supplier PageEnasidenib (AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
More Information Supplier PageEnasidenib (AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
More Information Supplier PageEnasidenib (AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
More Information Supplier PageEnavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
More Information Supplier PageEnavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
More Information Supplier PageEnavatuzumab (Anti-TNFRSF12A / TWEAKR / CD266) is a humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. MW : 150 kD.
More Information Supplier PageEncelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG3). It has potential immune checkpoint inhibitory and antineoplastic, antitumor activity. MW :144.58 KD.
More Information Supplier PageEncelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG3). It has potential immune checkpoint inhibitory and antineoplastic, antitumor activity. MW :144.58 KD.
More Information Supplier PageEncelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody targeting the inhibitory receptor lymphocyte activation gene 3 protein (LAG3). It has potential immune checkpoint inhibitory and antineoplastic, antitumor activity. MW :144.58 KD.
More Information Supplier PageEncenicline (EVP-6124) hydrochloride is a selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
More Information Supplier PageEncenicline (EVP-6124) hydrochloride is a selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
More Information Supplier PageEncequidar (HM30181, HM30181A) is a potent and selective inhibitor of the adenosine triphosphate-binding cassette transporter P-glycoprotein (P-gp).
More Information Supplier PageEncequidar (HM30181, HM30181A) is a potent and selective inhibitor of the adenosine triphosphate-binding cassette transporter P-glycoprotein (P-gp).
More Information Supplier PageEnclomiphene citrate is the trans isomer of clomiphene citrate and acts as a non-steroidal estrogen receptor antagonist.
More Information Supplier PageEnclomiphene citrate is the trans isomer of clomiphene citrate and acts as a non-steroidal estrogen receptor antagonist.
More Information Supplier PageEnclomiphene citrate is the trans isomer of clomiphene citrate and acts as a non-steroidal estrogen receptor antagonist.
More Information Supplier PageEnclomiphene citrate is the trans isomer of clomiphene citrate and acts as a non-steroidal estrogen receptor antagonist.
More Information Supplier PageEnclomiphene citrate is the trans isomer of clomiphene citrate and acts as a non-steroidal estrogen receptor antagonist.
More Information Supplier PageEncorafenib is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. Phase 3.
More Information Supplier PageEncorafenib is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. Phase 3.
More Information Supplier PageEncorafenib is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. Phase 3.
More Information Supplier PageEncorafenib is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. Phase 3.
More Information Supplier PageEncorafenib is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. Phase 3.
More Information Supplier PageEncorafenib is a highly potent RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing B-RAF(V600E) with EC50 of 4 nM. Phase 3.
More Information Supplier PageA unique collection of 175 endoplasmic reticulum stress (ER stress) related compounds used for high throughput screening(HTS) and high content screening(HCS).
More Information Supplier PageEndovion (NS 3728, SCO-101) is a potent anion channel inhibitor that blocks the Volume Regulated Anion Channels (VRAC).
More Information Supplier PageEndoxifen E-isomer (E-Endoxifen), an E-isomer of Endoxifen and impurity in Endoxifen Z-isomer drug substance, exhibits antiestrogenic effects.
More Information Supplier PageEndoxifen E-isomer (E-Endoxifen), an E-isomer of Endoxifen and impurity in Endoxifen Z-isomer drug substance, exhibits antiestrogenic effects.
More Information Supplier PageEndoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
More Information Supplier PageEndoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
More Information Supplier PageEndoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
More Information Supplier PageEndoxifen HCl, the active metabolite of Tamoxifen, ia a potent and selective estrogen receptor antagonist. Phase 2.
More Information Supplier PageEnfortumab (Anti-Nectin-4) is a monoclonal antibody targeting Nectin-4 and has potential for research into urothelial cancer. MW: 145.44 kD.
More Information Supplier PageEnfortumab (Anti-Nectin-4) is a monoclonal antibody targeting Nectin-4 and has potential for research into urothelial cancer. MW: 145.44 kD.
More Information Supplier PageEnfortumab (Anti-Nectin-4) is a monoclonal antibody targeting Nectin-4 and has potential for research into urothelial cancer. MW: 145.44 kD.
More Information Supplier PageEnfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma.
More Information Supplier PageEnfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma.
More Information Supplier PageEnfuvirtide Acetate (T20 Acetate, DP178 Acetate) is an HIV fusion inhibitor with ic50s of 13.63 nM and 30.21 nM on infection by HIV-1IIIB in MT-2 cells and HIV-1Bal in M7 cells, respectively.Solutions are unstable and should be fresh-prepared.
More Information Supplier PageEngeletin (Dihydrokaempferol 3-rhamnoside), a bioactive flavonoid, has multiple biological activities such as anti-diabetic and anti-inflammatory effects. engeletin againsts LPS-stimulated endometritis in mice via negative regulation of pro-inflammatory mediators via the TLR4-regulated NF-κB pathway.
More Information Supplier PageEnibarcimab (Anti-Adrenomedullin) is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody targeting the vasoprotective peptide adrenomedullin. It can be used for acute heart failure, COVID-19 infections and septic shock research. MW : 145.5 KD.
More Information Supplier PageEnibarcimab (Anti-Adrenomedullin) is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody targeting the vasoprotective peptide adrenomedullin. It can be used for acute heart failure, COVID-19 infections and septic shock research. MW : 145.5 KD.
More Information Supplier PageEnibarcimab (Anti-Adrenomedullin) is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody targeting the vasoprotective peptide adrenomedullin. It can be used for acute heart failure, COVID-19 infections and septic shock research. MW : 145.5 KD.
More Information Supplier PageEnitociclib (BAY 1251152) is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of […]
More Information Supplier PageEnitociclib (BAY 1251152) is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of […]
More Information Supplier PageEnitociclib (BAY 1251152) is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of […]
More Information Supplier PageEnitociclib (BAY 1251152) is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of […]
More Information Supplier PageEnitociclib (BAY 1251152) is a potent PTEFb/CDK9 inhibitor with an IC50 value of 3 nM for CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. BAY1251152 binds to and blocks the phosphorylation and kinase activity of CDK9, thereby preventing PTEFb-mediated activation of RNA Pol II and leading to the inhibition of […]
More Information Supplier PageENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to RET, SRC, NTRK1/TRKA, CSF1R/FMS, VEGFR2/KDR, FGFR and PDGFRα. ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines […]
More Information Supplier PageENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to RET, SRC, NTRK1/TRKA, CSF1R/FMS, VEGFR2/KDR, FGFR and PDGFRα. ENMD-2076 inhibits the growth of a wide range of human solid tumor and hematopoietic cancer cell lines […]
More Information Supplier Page
